Department of Medicine, Division of Endocrinology, Stanford University School of Medicine, Stanford, CA 94305-5103, USA.
Endocrinol Metab Clin North Am. 2010 Jun;39(2):401-18, table of contents. doi: 10.1016/j.ecl.2010.02.011.
Calcitriol (1,25-dihydroxyvitamin D(3)), the hormonally active form of vitamin D, exerts growth inhibitory and prodifferentiating effects on many malignant cells and retards tumor growth in animal models. Calcitriol is being evaluated as an anticancer agent in several human cancers. The mechanisms underlying the anticancer effects of calcitriol include inhibition of cell proliferation, stimulation of apoptosis, suppression of inflammation, and inhibition of tumor angiogenesis, invasion, and metastasis. This review discusses some of the molecular pathways mediating these anticancer actions of calcitriol and the preclinical data in cell culture and animal models. The clinical trials evaluating the use of calcitriol and its analogues in the treatment of patients with cancer are described. The reasons for the lack of impressive beneficial effects in clinical trials compared with the substantial efficacy seen in preclinical models are discussed.
骨化三醇(1,25-二羟维生素 D(3)),维生素 D 的活性形式,对许多恶性细胞具有生长抑制和促进分化作用,并可延缓动物模型中的肿瘤生长。骨化三醇正在多种人类癌症中被评估为一种抗癌药物。骨化三醇的抗癌作用机制包括抑制细胞增殖、刺激细胞凋亡、抑制炎症以及抑制肿瘤血管生成、侵袭和转移。本文讨论了介导骨化三醇这些抗癌作用的一些分子途径,以及细胞培养和动物模型中的临床前数据。本文还描述了评估使用骨化三醇及其类似物治疗癌症患者的临床试验。讨论了与临床前模型中观察到的显著疗效相比,临床试验中缺乏令人印象深刻的有益效果的原因。